Japan-based Takeda Pharmaceutical Company Limited and its wholly owned subsidiary, Takeda Pharmaceuticals North America, have established Takeda Canada, expanding the company’s North American presence. Takeda Canada will be
Eli Lilly and Company has announced inconclusive Phase II clinical trial results from Study HBBI investigating LY2140023 monohydrate, also known as mGlu2/3, for the treatment of patients suffering
Bayer has announced the launch of a new titration pack for patients with multiple sclerosis that is intended to make it easier for them to start Betaferon therapy.
The CAFC denied a Third Wave cross-appeal of the antitrust decision in favor of QIAGEN Gaithersburg and upheld a January 2008 ruling by Judge Barbara B. Crabb of
GlycoMimetics, a clinical stage pharmaceutical company, has completed two Phase I safety studies of its lead drug candidate GMI-1070 for vaso-occlusive crisis of sickle cell disease. The Phase
Mylan, a US-based generic pharmaceutical company, has announced its plans to purchase the remaining interest in India-based pharmaceutical company Matrix Laboratories from minority shareholders pursuant to a voluntary
Mylan, a generic pharmaceutical company, has announced that it and/or a subsidiary has been sued in connection with four separate first-to-file abbreviated new drug applications filed with the
According to the company, with its intelligent traffic light system, Biotronik Home Monitoring provides efficient and convenient remote monitoring of patients with implantable cardiac devices. Biotronik Home Monitoring
Toctino is a new once-daily oral treatment for adults with severe chronic hand eczema unresponsive to potent topical corticosteroids. The marketing authorization application (MAA) for Toctino was submitted
Kinetic Concepts (KCI) said that the initiatives will enhance its potential to increase shareholder value and improve operational efficiency and effectiveness by streamlining its organizational structure and workforce
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.